Exercise hormone irisin alleviates rheumatoid arthritis by removing dysfunctional mitochondria

Rheumatoid arthritis (RA) is a painful autoimmune disease where the immune system attacks the joints, causing chronic inflammation and progressive damage. Clinicians have long observed that regular exercise improves RA outcomes, but the biological reasons have been unclear. This study focuses on irisin, a hormone released by muscle during exercise, and tests whether it can therapeutically reduce arthritis severity in mice. The researchers found that irisin binds to specific proteins on the cell surface (ITGAV and ITGB5) and triggers a cellular 'clean-up' process called mitophagy, which selectively removes damaged or dysfunctional mitochondria. By clearing these faulty mitochondria, irisin prevents the leakage of mitochondrial DNA and harmful reactive oxygen species (ROS) into the cell interior, which would otherwise activate a powerful inflammatory complex called the NLRP3 inflammasome. Crucially, when mice were engineered to lack the essential autophagy gene Atg5 specifically in myeloid immune cells, irisin's protective effects were largely abolished—confirming that mitophagy is the key mechanism. The findings offer a plausible molecular explanation for exercise-related benefits in RA and suggest irisin or mitophagy-activating agents could be developed as treatments.

• Irisin treatment significantly reduced arthritis severity in two independent mouse models: K/BxN serum-transfer arthritis and collagen-induced arthritis (CIA), both established benchmarks for preclinical RA research.
• Irisin mechanistically engages ITGAV (integrin subunit alpha V) and ITGB5 (integrin subunit beta 5) as its cell-surface receptors to initiate mitophagy, providing a specific receptor-ligand pathway linking exercise to mitochondrial quality control.
• Mitophagy activation by irisin cleared leaked mitochondrial DNA (mtDNA) and reactive oxygen species (ROS), thereby suppressing NLRP3 inflammasome activation—a central driver of joint inflammation in RA.
• Conditional knockout of Atg5 in myeloid cells (atg5fl/fl Lyz2-Cre mice) abolished irisin's anti-arthritic benefits, genetically confirming that the mitophagy pathway (rather than an off-target effect) mediates the therapeutic response.
• The study positions mitophagy as a mechanistic bridge between the systemic benefits of physical exercise and reduced autoimmune joint pathology, an underexplored connection in RA biology.

This is a preclinical mechanistic study using two well-validated mouse models of RA: K/BxN serum-transfer arthritis (acute, innate-driven) and collagen-induced arthritis (CIA; chronic, adaptive-driven). Irisin was administered exogenously to arthritic mice, and disease outcomes were assessed alongside molecular analyses of mitophagy flux, mtDNA release, ROS levels, and NLRP3 inflammasome activation. Genetic confirmation used myeloid-specific Atg5 conditional knockout mice (atg5fl/fl crossed with Lyz2-Cre) to test the necessity of autophagy machinery for irisin's effects. Specific sample sizes, dosing regimens, and duration of treatment are not detailed in the abstract and would require review of the full manuscript.

Because this study is entirely conducted in mouse models, it is unknown whether irisin exerts the same ITGAV/ITGB5-mitophagy axis in human synovial macrophages or fibroblasts, which differ substantially from murine counterparts in RA pathophysiology. The study does not report pharmacokinetic data for irisin (bioavailability, half-life, effective dose range), which are critical barriers to translational development. It remains unclear whether circulating irisin levels achieved by exercise in humans are sufficient to activate the observed mitophagy cascade, or whether pharmacological dosing would be required. Future experiments should include human synovial tissue explants or patient-derived macrophages, and ideally a humanised mouse model, to bridge the gap toward clinical relevance.

This article directly extends [§136], which demonstrates that enhancing mitophagy via hirudin suppresses NLRP3 inflammasome activation during peripheral nerve repair—the same mitophagy→NLRP3 suppression logic is now shown to operate in synovial immune cells under irisin stimulation in RA. It parallels [§99], which establishes that mitochondrial RNA and DNA release during aging drives sterile inflammation and senescence, reinforcing the concept that mtDNA leakage is a conserved pathogenic signal that mitophagy must clear to resolve inflammatory disease. The study also parallels [§28], which shows that mitochondrial reprogramming of T helper cells is a key immunomodulatory mechanism in autoimmune-adjacent disease (asthma), suggesting mitochondrial quality control is a broader theme in immune dysregulation. Taken together with [§71], which frames mitochondrial dysfunction as a central pathogenic driver across diverse chronic diseases, the current article contributes a mechanistically resolved example of how a physiological signal (exercise/irisin) can therapeutically correct mitochondrial dysfunction in an autoimmune context.

• Hirudin Promotes Peripheral Nerve Repair by Enhancing Mitophagy to Suppress NLRP3 Inflammasome Activation
  Direct mechanistic parallel: hirudin also activates mitophagy to suppress NLRP3 inflammasome, but in a neural-repair context—comparing the two isolates whether the mitophagy→NLRP3 axis is a general anti-inflammatory mechanism or disease-specific.
• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Establishes that mitochondrial nucleic acid (mtRNA/mtDNA) release is a root cause of sterile inflammation and senescence, providing conceptual scaffolding for why clearing mtDNA via mitophagy (as irisin does) should dampen RA pathology.
• Small extracellular vesicle signaling and mitochondrial transfer reprogram T helper cell function in human asthma
  Shows mitochondrial reprogramming reshapes adaptive immune (T helper) cell function in asthma, raising the question of whether irisin's mitophagy effects in RA extend beyond myeloid cells to lymphocytes—a gap this paper does not address.
• The Role of Mitochondria in Polycystic Kidney Disease
  Provides a disease-agnostic framework for mitochondrial dysfunction as a pathogenic driver across chronic conditions; comparing with this RA study reveals both shared mechanisms and disease-specific nodes that could be therapeutic targets.
• Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
  Urolithin A (a mitophagy inducer tested in a placebo-controlled human trial) represents a translational benchmark: comparing its clinical mitophagy-activation data against irisin's preclinical findings highlights the evidence gap that remains before irisin can be considered a viable therapeutic.